Convalescent Plasma in Hospitalized COVID-19 Patients

Summary

The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to plasma infusion.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications